SCHEMBL625298

SCHEMBL625298

C=CCNC(=N)NO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506053 0.86 ALDH1A1 (0.48)
SCHEMBL14289025 0.77
SCHEMBL5580158 0.77
SCHEMBL7996738 0.77
SCHEMBL245633 0.73 ALDH1A1 (0.48)
SCHEMBL6589055 0.72
Hydrochloric Acid SCHEMBL8916103 0.72 TSHR (0.46)
SCHEMBL7047690 0.72
SCHEMBL5969554 0.72 TSHR (0.46)
SCHEMBL729436 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123354-A1 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2013-05-16 US claimed
US-20100144864-A1 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2010-06-10 US claimed
WO-2008124505-A2 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS,INC. (US) 2008-10-16 WO claimed
US-20240228520-A9 PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2024-07-11 US disclosed
US-20240207265-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC. 2024-06-27 US disclosed
US-20240208979-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2024-06-27 US disclosed
US-20240132528-A1 PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2024-04-25 US disclosed
EP-3762389-B1 CRYSTALLINE FORMS OF AN SGC STIMULATOR TISENTO THERAPEUTICS INC (US) 2024-02-28 EP disclosed
EP-3538096-B1 TREATMENT OF CNS DISEASES WITH SGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-11897887-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2024-02-13 US disclosed
EP-3481837-B1 PHOSPHORUS PRODRUGS OF SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-12-06 EP disclosed
US-20110160225-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-30 US disclosed
US-20100215779-A1 Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention IRONWOOD PHARMACEUTICALS, INC. 2010-08-26 US disclosed
US-20100190230-A1 Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability NORTHWESTERN UNIVERSITY 2010-07-29 US disclosed
WO-2010085749-A2 POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS WITH IMPROVED MEMBRANE PERMEABILITY NORTHWESTERN UNIVERSITY (US) 2010-07-29 WO disclosed
US-20100144864-A1 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2010-06-10 US disclosed
EP-2152266-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION Ironwood Pharmaceuticals, Inc. (US) 2010-02-17 EP disclosed
US-20090054450-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
WO-2008137318-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION IRONWOOD PHARMACEUTICALS, INC. (US) 2008-11-13 WO disclosed
WO-2008124505-A2 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS,INC. (US) 2008-10-16 WO disclosed